Charles Anthony Cary Pickering
Chairman at The Medicines Evaluation Unit Ltd.
Network origin in Charles Anthony Cary Pickering first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
North West Lung Centre
 North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities.
8
| Non-Profit Organization | Medical/Nursing Services | 8 |
The Medicines Evaluation Unit Ltd.
 The Medicines Evaluation Unit Ltd. Miscellaneous Commercial ServicesCommercial Services The Medicines Evaluation Unit Ltd. offers clinical trial solutions. It provides clinical trials and early phase exploratory studies in the pharmaceutical, scientific and clinical sectors. The firm specializes in performing clinical trials in respiratory and inflammatory medicine and related areas as well as conducting healthy volunteer, bioequivalence and SAD/MAD studies. The company is headquartered in Manchester, the United Kingdom.
4
| Subsidiary | Miscellaneous Commercial Services | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Charles Anthony Cary Pickering via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Reacta Biotech Ltd.
 Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | Miscellaneous Commercial Services | Founder | |
| Axalbion SA | Chairman | ||
Axalbion Therapeutics Ltd.
 Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Biotechnology | Chairman |
Statistics
International
| United Kingdom | 3 |
| Switzerland | 2 |
Sectoral
| Commercial Services | 2 |
| Health Technology | 2 |
Operational
| Director/Board Member | 12 |
| Chairman | 3 |
| Chief Operating Officer | 1 |
| Corporate Secretary | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Most connected contacts
- Stock Market
- Insiders
- Charles Anthony Cary Pickering
- Company connections
